Exonate Overview

  • Founded
  • 2013

Founded
  • Status
  • Private

  • Employees
  • 20

Employees
  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $1.9M

  • Investors
  • 15

Exonate General Information

Description

Provider of biopharmaceutical services intended to improve the treatment of patients with retinal vascular diseases and to transform the lives of those suffering from vision loss. The company's services offer lead program molecules, for wet Age-Related Macular Degeneration (wet AMD), act via a novel mechanism of action to inhibit pathological blood vessels and reduce the formation of pathological Vascular Endothelial Growth Factor without inhibiting beneficial, non-pathological VEGF, enabling doctors to focus on developing novel therapies for wet age-related macular degeneration.

Contact Information

Website
www.exonate.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • WTL Moorfield Road
  • Duxford
  • Cambridge CB22 4PS
  • England, United Kingdom
+44 01223 000000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Exonate Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 03-Jan-2019 $1.9M 00.000 Completed Generating Revenue
5. Later Stage VC 12-Sep-2018 00.000 00.000 00.000 Completed Clinical Trials - Phase 1
4. Grant 06-Feb-2017 00.000 00.000 Completed Clinical Trials - Phase 1
3. Early Stage VC 01-Dec-2016 00.00 00.000 00.000 Completed Clinical Trials - Phase 1
2. Early Stage VC 05-Oct-2015 $1.21M $1.87M 00.000 Completed Clinical Trials - Phase 1
1. Seed Round 01-Mar-2014 $651K $651K 00.000 Completed Clinical Trials - Phase 1
To view Exonate’s complete valuation and funding history, request access »

Exonate Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 00,000 00.000000 0000.00 0000.00 00 0000.00 00.000
Ordinary 00,000 00.000000 000.00 000.00 00 000.00 00.000
Ordinary 14,141 $0.012877 $72.11 $72.11 1x $72.11 17.79%
Ordinary 7,860 $0.012877 $64.39 $64.39 1x $64.39 9.89%
To view Exonate’s complete cap table history, request access »

Exonate Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Provider of biopharmaceutical services intended to improve the treatment of patients with retinal vascular diseases and
Drug Discovery
Cambridge, United Kingdom
20 As of 2022
00.000
0000000000 0 00.000

000000

ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse
0000 000000000
London, United Kingdom
000 As of 0000
00000
0.00 0000-00-00
000000&0 00000

000000

nim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequ
0000000000000
Leuven, Belgium
00 As of 0000
0000
000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Exonate Competitors (20)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Gyroscope Formerly VC-backed London, United Kingdom 000 00000 000000&0 00000
0000000 Corporation Leuven, Belgium 00 0000 000000000 0000
00000000 000000 Formerly VC-backed Farmington Hills, MI 0 000.00 000000000 000.00
000 000000000000 Venture Capital-Backed Ann Arbor, MI 00 000.00 00000000000 000.00
0000000 0000000000 Formerly VC-backed Cambridge, MA 0000 00.000 0000 00.000
You’re viewing 5 of 20 competitors. Get the full list »

Exonate Patents

Exonate Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202010829-D0 Compounds for treatment of neovascular diseases Inactive 14-Jul-2020 0000000000
GB-201912449-D0 Compounds for treatment of neovascular diseases Inactive 30-Aug-2019
GB-201810765-D0 Srpk1 inhibitors Inactive 29-Jun-2018
GB-201715637-D0 Srpk1 inhibitors Inactive 27-Sep-2017
CA-3077749-A1 Srpk1 inhibitors Pending 27-Sep-2017 C07D401/12
To view Exonate’s complete patent history, request access »

Exonate Executive Team (6)

Name Title Board Seat Contact Info
Loic Lhuillier Ph.D Chief Operating Officer
David Bates Ph.D Co-Founder, Chief Scientific Officer and Board Member
Christopher O'Connor Financial Controller
Steven Harper Medical Director and Board Member
Lucy Donaldson Ph.D Co-Founder and Founding Scientist
You’re viewing 5 of 6 executive team members. Get the full list »

Exonate Board Members (9)

Name Representing Role Since
Andrew Garland Ph.D Self Board Member 000 0000
Andrew Naylor Self Board Member 000 0000
Christopher Torrance Ph.D Self Board Member 000 0000
David Bates Ph.D Exonate Co-Founder, Chief Scientific Officer and Board Member 000 0000
John Kurek Ph.D Uniseed Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Exonate Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Exonate Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Stoic Venture Capital Venture Capital Minority 000 0000 000000 0
University of Bristol Endowment Limited Partner Minority 000 0000 000000 0
R42 Group Venture Capital Minority 000 0000 000000 0
Wellcome Trust Limited Partner 000 0000 000000 0
Martlet Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 15 investors. Get the full list »